ClinicalTrials.gg
CompletedNCT03460743Updated Nov 13, 2019

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

A Phase 3 interventional study of Study group - quadrivalent recombinant hemagglutinin influenza vaccine and Control group - quadrivalent inactivated influenza vaccine in Influenza, Human, sponsored by Laboratorios Liomont. Completed at 11 sites in Mexico. Open to participants aged 3 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Laboratorios Liomont · Phase 3, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,556
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Influenza, Human with a site in Mexico — 1 open to participants now, 1 under way, 1 of them phase 3. Influenza, Human · Mexico.

Enrollment
13th of 33
1,556 · median 654
Started
2018
with 3 others
Phase 3
22 of 35
1 open now
Registered
30th of 35
by date

Among the 35 studies in Influenza, Human with a site in Mexico, this one is the 13th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2018, is one of 22 in phase 3, and was the 30th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

1 of the 35 studies in Influenza, Human with a site in Mexico is open now. Recruiting first, the newest first:

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Influenza, Human with a site in Mexico, or all of them as a file.
02

Study summary

Multicentric study, Phase III; this study is a randomized, participant- and observer-blind, parallel group evaluation to evaluate the immunogenicity, relative efficacy, safety and reactogenicity of a recombinant quadrivalent hemagglutinin influenza vaccine versus an inactivated quadrivalent influenza vaccine in pediatric subjects and adolescents of 3-17 years of age. Investigational vaccine is indicated for active immunization against influenza A and B for strains contained in the vaccine marketed in the United States for persons 18 years of age or older.

Read the detailed description

Abbreviated title Evaluation of immunogenicity, relative efficacy, safety and reactogenicity of Flublok Quadrivalent® in healthy children and adolescents aged 3 to17 years.

Sponsor Product Identifiers Flublok® Quadrivalent of Laboratories Liomont, S.A. de C.V.

Flublok Quadrivalent consists of 180 μg total recombinant hemagglutinins Study Phase Phase 3 Study National multicentric Participating sites: Mexico: At least 10 research sites distributed in different states.

Clinical indication Vaccine indicated for active immunization against influenza A and B for strains contained in the vaccine; authorized in the United States for persons 18 years of age or older.

It will be evaluated in a population aged 3 to 17 years. Treatment Groups Flublok® Quadrivalent (research product) Fluzone® Quadrivalent (active comparator) Number of participants in the study 1,556 Estimated study duration: 25 months Duration of participation 6 months Randomization ratio 1:1 Study visits Visit 1: It corresponds to the screening visit, baseline blood sampling and administration of the study vaccine that can be performed on Day 0.

Visit 1A and 2: Remote contacts on day 2 and 7 post-vaccination. Visit 3: i. Follow up and blood sampling (for the 1-dose group); ii. Visit 3A, follow-up and application of the second dose of the vaccine (for the corresponding group); iii. Visit 3B, follow-up and blood sampling for the 2-dose group. The visits occur on Day 28.

Months 3, 4, 5: Remote Contacts for safety tracking Visit 4: Remote contact for study closure and safety tracking at Month 6. Statistical analysis plan • Primary efficacy analysis: Proportion of subjects in each age category and vaccine group who seroconvert, with seroconversion being defined as (a) a >4-fold rise in HAI antibody titer in those subjects seropositive (titer >10) at baseline or (b) achievement of an HAI titer of >40 in those seronegative at baseline. Seroconversion will be evaluated against each of the 4 vaccine antigens, on Study Day 28 (or Day 56 for 2-dose subjects), by category A and B separated

  • Geometric Mean Titer (GMT) of HAI antibody against each vaccine antigen in each age category and vaccine group 28 days after immunization (Day 56 for 2-dose subjects) by category A and B separated Secondary efficacy analysis. Efficacy analysis and analysis of safety results associated to reactogenicity and other adverse events.

Final contribution of the study results The direct benefit for subjects, individually, is expected to be seasonal influenza protection with the expected degree of protection, specially among recipients of the IIV4 control vaccine, which is also approved for use in the age groups of the study population, evaluating in detail the comparative response of the research product.

The results of the study are intended to evaluate the immunogenicity, efficacy and safety of Flublok Quadrivalent in this population age and in this way, support the use of Flublok Quadrivalent for children and adolescents 3-17 years of age.

If the results are favorable and if the hypothesis is fulfilled, the extension of the indication to the evaluated age segment may result in greater protection of the child population so as, not to be unprotected by the limited resources in health, the shortage of vaccines in certain regions, and to improve the supply and accessibility of the population in general for influenza prevention.

The hypothesis underlying the study design and sample size estimated for the trial population from 3 to 17 years of age is based on the immunogenicity of Flublok Tetravalent, considering that the haemagglutination inhibition (HAI) seroconversion titers and the geometric mean of post-vaccination titers for the four hemagglutinin antigens in the vaccines after completion of vaccination with Flublok Quadrivalent are not inferior to those titers observed in those vaccinated with IIV4.

Statistical considerations. sample size is 330 subjects in each age cohort for each treatment group, reaching a power of 80% to detect a marginal difference of non-inferiority for the seroconversion rate between the groups of -0.1000. The seroconversion rate of the control group is 0.7000. The Flublok Quadrivalent seroconversion rate is assumed to be 0.6000 under the null hypothesis of inferiority. The power was estimated for the case that the relative seroconversion rate of Flublok Quadrivalent is 0.7000. The statistical test use is a one tailed Z test (unpooled). The significance level for the test was established in 0.0250.

A total of 1,556 subjects (330 complete cases per treatment group in subjects from 3 to 17 years of age) will be enrolled, considering possible losses up to a maximum of 15%.

03

Conditions studied

  • Influenza, Human

Browse trials for

Keywords

  • hemagglutinin influenza vaccine
  • recombinant influenza vaccine
04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 3 to 17 years.
  • History of two previous influenza immunizations at any time, or influenza infection during the previous year.
  • Female subjects of (as defined by the onset of menses) must agree to prevent pregnancy and usage of an effective , or having practiced sexual abstinence for at least 28 day prior to the first study vaccine administration. Female subjects of child-bearing potential must be tested for pregnancy within 24 hours prior to vaccine administration.
  • In good general health, healthy or medically stable, as determined by the medical history, physical examination and the Investigator's judgment.
  • Parent(s) or legal representative of each potential subject must comprehend the study requirements, sign the before any procedure, and agree to comply with planned study procedures and visits. Provide written consent prior to enrollment and initiation of any study procedure.
  • Pediatric consent will be attained as per the Research Ethics Committee's determination when subject is aged 8 or older.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to eggs (anaphylaxis, angioedema, respiratory distress), severe allergy (e.g. anaphylaxis) to other components of the vaccine or to receive the comparator IIV4.
  • Use of systemic at doses of 2mg/kg/day for more than 10 days of prednisone or its equivalent.

(The use of nasal or topical steroids will be allowed).

  • Active neoplastic disease or a history of any .
  • History of receiving the influenza vaccine within the previous 6 months.
  • Plan to receive another influenza vaccine, during the study term.
  • History of receiving immunoglobulin or another blood product within the 3 months prior to enrollment in this study.
  • Acute or chronic medical condition that, in the opinion of the Investigator, would render immunization unsafe or would interfere with the evaluation of efficacy or the immune response to the vaccine.
  • An acute illness, including a body temperature greater than 37.7°C, within 3 days prior to immunization.
  • Receive an experimental vaccine or medication within 1 month prior to enrollment in this study, or the expectation to receive an experimental vaccine, medication, or blood product during the study period.
  • Developmental delay, neurologic disorder, or seizure disorder requiring ongoing medical assistance (note: history of febrile seizure is not considered an exclusion criterion).
  • History of Guillain-Barré syndrome within 6 weeks after the application a previous influenza vaccine.
  • Concurrent participation in another clinical trial (active or follow-up phase).
  • Any other condition or situation that would, in the opinion of the investigator, place them at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,556 participants (actual)

Study arms

  • Experimental
    Study group

    single or two doses of quadrivalent recombinant 180 ugm hemagglutinin influenza vaccine

    Biological: Study group - quadrivalent recombinant hemagglutinin influenza vaccine

  • Active comparator
    Control group

    single or two doses of quadrivalent inactivated influenza vaccine.

    Biological: Control group - quadrivalent inactivated influenza vaccine

Interventions

  • BiologicalStudy group - quadrivalent recombinant hemagglutinin influenza vaccine

    Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.

  • BiologicalControl group - quadrivalent inactivated influenza vaccine

    Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.

06

What researchers measure

Primary outcomes

  1. Seroconversion

    Proportion of subjects with seroconversion defined as (a) a \>4-fold rise in HAI antibody titer in subjects seropositive (titer \>10) at baseline or (b) an HAI titer of \>40 in those seronegative at baseline.

    Time frame: To be evaluated against each of the 4 vaccine antigens, on Day 28 (or Day 56 for 2-dose subjects), by category aged

07

Study locations

11 sites
  • Clinical Research Institute Saltillo
    Saltillo, Coahuila 25020, Mexico
  • Centro de Investigacion Clinica del Pacifico
    Acapulco, Guerrero 39670, Mexico
  • AMIC Pachuca
    Pachuca, Hidalgo 42070, Mexico
  • Instituto Jalisciencie de Metabolismo
    Guadalajara, Jalisco 44670, Mexico
  • AINPAD Morelia
    Morelia, Michoacan 58070, Mexico
  • JM Research
    Cuernavaca, Morelos 62290, Mexico
  • Instituto Nacional de Pediatria
    Mexico City, 04530, Mexico
  • CEMDEC
    Mexico City, 06100, Mexico
  • Clinical Research Institute Darwin
    Mexico City, 11590, Mexico
  • UDEP Puebla
    Puebla, 72160, Mexico
  • Centro Especializado en Investigación Clínica CEIC
    Veracruz, 94290, Mexico
08

References and documents

Publications

  • King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27. PubMed 19716456 ↗
  • Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28. PubMed 21277410 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Oct 2019, 19 months.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 19 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2018
First posted
Mar 9, 2018
StartActual
Mar 22, 2018
Primary completionActual
Oct 22, 2019
CompletionActual
Oct 22, 2019
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03460743
Lead sponsor
Laboratorios Liomont
Collaborators
EPIC Research CRO, ILS Clinical Research, Q Square Solutions
Responsible party
Sponsor
First posted
Mar 9, 2018
Start date
Mar 22, 2018
Primary completion
Oct 22, 2019
Completion
Oct 22, 2019
Last update
Nov 13, 2019

Study contacts

Mercedes Macias, MD
study chair · National Institute of Pediatrics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion